Accelerating Drug Monetization: PTS Expands in China Market, UnicoCell Completes FDA Registration
Taiwanese biotech companies are accelerating new drug commercialization. PTS partnered with a Chinese firm to promote its lung cancer drug, while UnicoCell completed US FDA DMF registration for its stem cell and exosome ingredients.
📋 Article Processing Timeline
- 📰 Published: April 24, 2026 at 18:28
- 🔍 Collected: April 24, 2026 at 19:02 (33 min after Published)
- 🤖 AI Analyzed: April 24, 2026 at 21:04 (2h 2m after Collected)
Central News Agency
(CNA Reporter Ho Hsiu-ling, Taipei, 24th) Taiwanese biotech companies are accelerating the commercialization and strategic deployment of new drugs. PTS (共信-KY) announced the signing of a new drug promotion and licensing agreement with a Chinese partner to expand the lung cancer drug market. Meanwhile, UnicoCell (永立榮生醫) completed the Drug Master File (DMF) registration with the US FDA for its active pharmaceutical ingredients, paving the way for subsequent clinical reviews and international licensing to accelerate drug monetization.
PTS announced a major market strategy adjustment today. Its subsidiary, Tianjin Red Sun Jiandakang Pharmaceutical Technology Co., Ltd. (referred to as Tianjin Red Sun), has finalized a mainland China market promotion cooperation agreement with Zhenshi Biopharmaceutical Technology (Zhuhai) Co., Ltd. (referred to as Zhenshi Bio).
PTS stated that it is optimistic about Zhenshi Bio's focus on commercializing products in the oncology disease sector. Last year, PTS's new lung cancer drug was included in the first edition of China's 2025 "Commercial Health Insurance Innovative Drug Directory." This allows it to be covered by commercial insurance, reducing out-of-pocket expenses for patients and helping to accelerate its market penetration and sales growth in the Chinese market.
UnicoCell announced that its two active amniotic fluid stem cell preparations—amniotic fluid stem cells and exosomes—have received Drug Master File (DMF) registration from the US Food and Drug Administration (US FDA).
UnicoCell stated that amniotic fluid stem cells and exosomes are the main active ingredients for a new erectile dysfunction drug and a new exosome drug, respectively, both of which are currently undergoing Phase 2a clinical trials. Obtaining the DMF registration indicates that the submitted data regarding active ingredients and manufacturing processes has received preliminary recognition from the FDA, laying a solid foundation for the subsequent review processes of its products. (Editor: Chang Liang-chih) 1150424
Stand with facts; every sponsorship you give is the power to protect press freedom.
Download the CNA "First-hand News" APP to grasp the latest news instantly.
The text, images, and audio/video of this website may not be reproduced, broadcast publicly, or transmitted and utilized publicly without authorization.
(CNA Reporter Ho Hsiu-ling, Taipei, 24th) Taiwanese biotech companies are accelerating the commercialization and strategic deployment of new drugs. PTS (共信-KY) announced the signing of a new drug promotion and licensing agreement with a Chinese partner to expand the lung cancer drug market. Meanwhile, UnicoCell (永立榮生醫) completed the Drug Master File (DMF) registration with the US FDA for its active pharmaceutical ingredients, paving the way for subsequent clinical reviews and international licensing to accelerate drug monetization.
PTS announced a major market strategy adjustment today. Its subsidiary, Tianjin Red Sun Jiandakang Pharmaceutical Technology Co., Ltd. (referred to as Tianjin Red Sun), has finalized a mainland China market promotion cooperation agreement with Zhenshi Biopharmaceutical Technology (Zhuhai) Co., Ltd. (referred to as Zhenshi Bio).
PTS stated that it is optimistic about Zhenshi Bio's focus on commercializing products in the oncology disease sector. Last year, PTS's new lung cancer drug was included in the first edition of China's 2025 "Commercial Health Insurance Innovative Drug Directory." This allows it to be covered by commercial insurance, reducing out-of-pocket expenses for patients and helping to accelerate its market penetration and sales growth in the Chinese market.
UnicoCell announced that its two active amniotic fluid stem cell preparations—amniotic fluid stem cells and exosomes—have received Drug Master File (DMF) registration from the US Food and Drug Administration (US FDA).
UnicoCell stated that amniotic fluid stem cells and exosomes are the main active ingredients for a new erectile dysfunction drug and a new exosome drug, respectively, both of which are currently undergoing Phase 2a clinical trials. Obtaining the DMF registration indicates that the submitted data regarding active ingredients and manufacturing processes has received preliminary recognition from the FDA, laying a solid foundation for the subsequent review processes of its products. (Editor: Chang Liang-chih) 1150424
Stand with facts; every sponsorship you give is the power to protect press freedom.
Download the CNA "First-hand News" APP to grasp the latest news instantly.
The text, images, and audio/video of this website may not be reproduced, broadcast publicly, or transmitted and utilized publicly without authorization.